Harry L. A. Janssen
#118,259
Most Influential Person Now
Harry L. A. Janssen's AcademicInfluence.com Rankings
Harry L. A. Janssenphilosophy Degrees
Philosophy
#5245
World Rank
#7997
Historical Rank
Logic
#2554
World Rank
#3565
Historical Rank
Download Badge
Philosophy
Harry L. A. Janssen's Degrees
- PhD Medicine University of Amsterdam
- Doctorate Medicine University of Amsterdam
Why Is Harry L. A. Janssen Influential?
(Suggest an Edit or Addition)Harry L. A. Janssen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. (2017) (2984)
- Treatment of HCV infection by targeting microRNA. (2013) (1981)
- Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. (2012) (1468)
- The Rotterdam Study: 2010 objectives and design update (2007) (1257)
- Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial (2005) (1160)
- Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis (2007) (618)
- Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma (2011) (526)
- Budd-Chiari syndrome: a review by an expert panel. (2003) (474)
- Etiology, management, and outcome of the Budd-Chiari syndrome. (2009) (458)
- Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. (1992) (411)
- Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. (2008) (383)
- Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. (2009) (375)
- Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. (2015) (368)
- Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. (2000) (367)
- The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. (2008) (354)
- Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. (2014) (346)
- Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. (2016) (341)
- Determinants of survival and the effect of portosystemic shunting in patients with Budd‐Chiari syndrome (2004) (341)
- Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B (2004) (332)
- The Rotterdam Study: 2012 objectives and design update (2011) (329)
- Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. (2011) (309)
- Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection (2003) (304)
- PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. (2016) (303)
- Hepatitis B virus infection (2018) (302)
- Extrahepatic portal vein thrombosis: aetiology and determinants of survival (2001) (302)
- TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. (2008) (301)
- Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. (2015) (299)
- Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. (2001) (285)
- Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. (2012) (285)
- Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. (2016) (279)
- Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus (2008) (270)
- Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype (2006) (255)
- The role of quantitative hepatitis B surface antigen revisited. (2017) (254)
- A global scientific strategy to cure hepatitis B. (2019) (253)
- Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study (2016) (248)
- The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
- Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels (2010) (242)
- Suicide associated with alfa-interferon therapy for chronic viral hepatitis. (1994) (237)
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (2018) (227)
- Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels (2013) (216)
- The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B (2017) (214)
- Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
- Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus (2009) (195)
- Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. (2010) (193)
- Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. (2012) (192)
- External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. (2013) (186)
- Hepatocyte‐derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation (2012) (185)
- Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. (2011) (184)
- Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase (2003) (177)
- Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis (2012) (174)
- Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. (2012) (171)
- Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response (2011) (167)
- Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. (2012) (166)
- Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. (2014) (156)
- Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment (1999) (153)
- Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. (2014) (153)
- Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi) (2011) (153)
- Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) (2015) (150)
- Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. (2011) (148)
- Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. (2015) (147)
- Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. (2010) (138)
- Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. (2016) (136)
- Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study (2015) (134)
- Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. (2014) (131)
- Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA‐122 levels without affecting other microRNAs in plasma (2016) (130)
- Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial (2021) (129)
- Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. (2010) (126)
- Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. (2017) (126)
- Hepatitis B Virus Lacks Immune Activating Capacity, but Actively Inhibits Plasmacytoid Dendritic Cell Function (2011) (125)
- Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. (2012) (125)
- Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. (2011) (124)
- Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study. (2016) (123)
- Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. (2010) (118)
- Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. (2017) (116)
- Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. (2014) (114)
- How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? (2017) (114)
- Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy (2005) (113)
- Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis (2008) (112)
- Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. (2007) (109)
- Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. (2019) (107)
- The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double‐blind, randomized, placebo‐controlled trial (2010) (107)
- Pathogenesis and Treatment of Budd-Chiari Syndrome Combined with Portal Vein Thrombosis (2006) (104)
- Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. (2009) (103)
- Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B (2020) (98)
- Vascular liver disorders (II): portal vein thrombosis. (2009) (96)
- Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. (2011) (95)
- Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes (2016) (94)
- Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. (2014) (94)
- The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. (2001) (94)
- Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. (2014) (94)
- Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia (2017) (93)
- Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. (2006) (93)
- Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? (2015) (91)
- Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B (2015) (90)
- A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. (2015) (90)
- Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long‐term cohort study (2012) (89)
- Anticoagulant therapy in patients with non‐cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding (2013) (88)
- A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B (2010) (88)
- Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease (2019) (88)
- Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study) (2019) (87)
- aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. (2020) (87)
- Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte‐derived microRNA‐122 (2013) (87)
- Mycophenolic acid augments interferon‐stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo (2012) (87)
- Kupffer cells express a unique combination of phenotypic and functional characteristics compared with splenic and peritoneal macrophages (2012) (86)
- Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients (2016) (86)
- Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study (2018) (85)
- Serum liver enzymes are associated with all‐cause mortality in an elderly population (2014) (84)
- Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests (2012) (84)
- Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. (2019) (83)
- Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). (2016) (80)
- IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expression. (2011) (78)
- microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. (2018) (77)
- Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? (2011) (76)
- Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. (2018) (75)
- Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. (2015) (75)
- Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors (2015) (75)
- The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation (2005) (74)
- Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis (2008) (73)
- Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. (2003) (73)
- Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2A and Adefovir (2013) (71)
- Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. (2012) (70)
- Immunology of hepatitis B and hepatitis C virus infections. (2008) (70)
- Treatment of chronic hepatitis B virus infection - Dutch national guidelines. (2008) (69)
- Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C (2010) (66)
- Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. (2004) (65)
- Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. (2016) (65)
- Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment (2018) (64)
- Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma (2013) (63)
- Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. (2020) (63)
- Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. (2010) (62)
- Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. (2019) (62)
- Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). (1993) (61)
- Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype (2012) (61)
- The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection (2003) (61)
- α-Galactosylceramide in Chronic Hepatitis B Infection: Results from a Randomized Placebo-Controlled Phase I/ II Trial (2009) (60)
- SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma (2014) (60)
- Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. (2016) (59)
- 58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION (2012) (59)
- Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. (1994) (58)
- A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. (2011) (58)
- New therapeutic agents for chronic hepatitis B. (2016) (58)
- Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome (2018) (57)
- Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years (2015) (57)
- Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C (2007) (57)
- Modulation of dendritic cell function by persistent viruses (2009) (57)
- Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. (2020) (57)
- Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study. (2017) (56)
- Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation—A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion (2017) (56)
- IFN‐λ‐mediated IL‐12 production in macrophages induces IFN‐γ production in human NK cells (2015) (56)
- Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. (2008) (56)
- Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. (2008) (56)
- Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. (2015) (56)
- Human CD34-Derived Myeloid Dendritic Cell Development Requires Intact Phosphatidylinositol 3-Kinase–Protein Kinase B–Mammalian Target of Rapamycin Signaling (2010) (55)
- Multiple biopsy passes and the risk of complications of percutaneous liver biopsy (2017) (55)
- PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC) (2014) (55)
- HCV infection and miravirsen. (2013) (54)
- Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. (2020) (54)
- Immunomodulatory therapy for chronic hepatitis B virus infection (2005) (53)
- Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy (2019) (52)
- Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response (2019) (52)
- Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. (2008) (52)
- Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. (2020) (52)
- Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history (2018) (52)
- Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (51)
- GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo (2015) (51)
- Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B (2016) (50)
- Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. (2016) (49)
- Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study (2017) (49)
- Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. (2006) (48)
- Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. (2013) (48)
- HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. (2018) (48)
- Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. (2009) (48)
- CD4+ CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. (2015) (47)
- Prediction of the response to peg‐interferon‐alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment (2010) (46)
- Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. (2005) (46)
- Combined antiviral activity of interferon-α and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing (2009) (46)
- The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. (2011) (46)
- Randomised clinical trial: anti‐viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV (2011) (46)
- Is there sufficient evidence to recommend antiviral therapy in hepatitis C? (2014) (46)
- Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON) (2017) (46)
- Determination of hepatitis B phenotype using biochemical and serological markers (2017) (46)
- Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. (2020) (46)
- Risk factors and outcome of HIV‐associated idiopathic noncirrhotic portal hypertension (2012) (45)
- Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam, The Netherlands. (2012) (45)
- The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. (2009) (45)
- Genetic characteristics of hepatitis B virus genotypes as a factor for interferon‐induced HBeAg clearance (2007) (44)
- The Role of Interferon in Hepatitis B Therapy (2010) (43)
- Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic HBV Infection: Systematic Review and Meta-analysis. (2020) (43)
- Peg‐interferon improves liver histology in patients with HBeAg‐positive chronic hepatitis B: no additional benefit of combination with lamivudine (2006) (42)
- Long‐term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd–Chiari syndrome (2008) (42)
- Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. (2019) (42)
- Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients (2005) (42)
- Seizures associated with low-dose α-interferon (1990) (41)
- A Nonredundant Role for Canonical NF-κB in Human Myeloid Dendritic Cell Development and Function (2010) (41)
- Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome. (2012) (41)
- Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. (2019) (41)
- Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. (2020) (41)
- Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? (2006) (41)
- Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. (2000) (40)
- Molecular characteristics of hepatitis B virus genotype a confer a higher response rate to interferon treatment (2001) (40)
- Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. (2004) (40)
- Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients (2010) (39)
- Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels? (2009) (39)
- Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis (2015) (39)
- The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection (2015) (39)
- Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. (2005) (39)
- Treatment of chronic hepatitis C virus infection - Dutch national guidelines. (2008) (38)
- Role of T cell immunity in hepatitis C virus infections. (2013) (38)
- Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis (2007) (38)
- Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct (2015) (37)
- Aspergillus osteomyelitis after liver transplantation: conservative or surgical treatment? (2000) (37)
- Viral dynamics during tenofovir therapy in patients infected with lamivudine‐resistant hepatitis B virus mutants (2005) (37)
- PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function. (2012) (37)
- Retention of CD4+ CD25+ FoxP3+ Regulatory T Cells in the Liver after Therapy-Induced Hepatitis C Virus Eradication in Humans (2011) (36)
- Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters (2014) (36)
- Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B (2021) (35)
- Increased N‐terminal cleavage of alpha‐2‐antiplasmin in patients with liver cirrhosis (2013) (35)
- Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients (2009) (35)
- Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
- Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
- Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). (2021) (34)
- Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response (2012) (33)
- A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. (2011) (33)
- Increased Prevalence of Advanced Liver Fibrosis in Patients with Psoriasis: A Cross-sectional Analysis from the Rotterdam Study. (2016) (33)
- Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection (2011) (32)
- The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long‐term clinical outcome in chronic hepatitis B patients (2015) (32)
- Flow cytometry of fine‐needle‐aspiration biopsies: a new method to monitor the intrahepatic immunological environment in chronic viral hepatitis (2005) (31)
- Successful Treatment with Peginterferon alfa-2b of HBeAg-positive HBV Non-Responders to Standard Interferon or Lamivudine (2006) (31)
- Microarray Expression Profiling of microRNAs Reveals Potential Biomarkers for Hepatocellular Carcinoma. (2018) (31)
- Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon-α Therapy for Chronic Hepatitis B (2007) (30)
- Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism (2016) (30)
- Can the model for end‐stage liver disease be used to predict the prognosis in patients with Budd‐Chiari syndrome? (2007) (30)
- Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. (2008) (30)
- γ‐Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon‐α‐2b in chronic hepatitis C non‐responders (2007) (30)
- New therapeutic opportunities for hepatitis C based on small RNA. (2007) (30)
- Potency of tenofovir in chronic hepatitis B: mono or combination therapy? (2008) (29)
- Monocytes from Chronic HBV Patients React In Vitro to HBsAg and TLR by Producing Cytokines Irrespective of Stage of Disease (2014) (29)
- Interferon‐α and zidovudine combination therapy for chronic hepatitis B: Results of a randomized, placebo‐controlled trial (1993) (29)
- Getting to HBV cure: The promising paths forward (2022) (29)
- Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B (2010) (28)
- Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: The Rotterdam Study. (2015) (28)
- Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States (2015) (28)
- Repeated courses of α-interferon for treatment of chronic hepatitis type B (1993) (28)
- The Intrahepatic T Cell Compartment Does Not Normalize Years After Therapy-Induced Hepatitis C Virus Eradication. (2015) (28)
- A dynamic perspective of RNAi library development. (2012) (27)
- Prothrombotic disorders in abdominal vein thrombosis. (2012) (27)
- Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir (2008) (27)
- Future prospectives for the management of chronic hepatitis B. (2007) (27)
- Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7 (2012) (26)
- ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B (2018) (26)
- Restoration of TLR3-Activated Myeloid Dendritic Cell Activity Leads to Improved Natural Killer Cell Function in Chronic Hepatitis B Virus Infection (2012) (26)
- Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. (1992) (26)
- Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B. (2020) (26)
- Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe‐antigen positive hepatitis B patients treated with interferon‐alpha (2006) (26)
- Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation (2017) (25)
- Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. (2011) (25)
- Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. (2016) (25)
- Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials (2019) (25)
- Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population (2020) (25)
- Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. (2019) (25)
- Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. (2007) (25)
- Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. (2019) (24)
- Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient‐Reported Outcomes (2018) (24)
- Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America (2021) (24)
- The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
- The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. (2006) (24)
- M2‐polarized tumor‐associated macrophages promote epithelial‐mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma (2020) (23)
- Human hepatic lymph nodes contain normal numbers of mature myeloid dendritic cells but few plasmacytoid dendritic cells. (2004) (23)
- Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection (2018) (23)
- Immunology of hepatitis C virus infections. (2012) (23)
- Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. (2006) (23)
- [3] A PROSPECTIVE FOLLOW-UP STUDY ON 163 PATIENTS WITH BUDD-CHIARI SYNDROME: RESULTS FROM THE EUROPEAN NETWORK FOR VASCULAR DISORDERS OF THE LIVER (EN-VIE) (2007) (23)
- Factor V Leiden mutation, prothrombin gene mutation and deficiencies in coagulation inhibitors associated with Budd‐Chiari syndrome and portal vein thrombosis (1998) (22)
- Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. (2003) (22)
- Prediction of long‐term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE‐B score (2017) (22)
- Branched oligosaccharide structures on HBV prevent interaction with both DC‐SIGN and L‐SIGN (2008) (22)
- Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. (2020) (22)
- Telaprevir/boceprevir era: from bench to bed and back. (2012) (22)
- Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. (2014) (22)
- Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis (2020) (22)
- Polymorphisms of HLA‐DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B (2014) (21)
- The number needed to treat to prevent mortality and cirrhosis‐related complications among patients with cirrhosis and HCV genotype 1 infection (2014) (21)
- An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B (2015) (21)
- The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir‐based regimens (2017) (21)
- Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. (2011) (21)
- HBsAg loss after peginterferon‐nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow‐up (2017) (21)
- Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B (2019) (21)
- Prospects of RNAi and microRNA-based therapies for hepatitis C (2009) (21)
- Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B (2020) (20)
- Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. (2007) (20)
- Quantitative assessment of hepatitis B virus DNA in chronic hepatitis B: comparison of two solution hybridization assays (1993) (20)
- An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. (2021) (20)
- Real life adherence of chronic hepatitis B patients to entecavir treatment. (2015) (20)
- Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen. (2008) (20)
- Intrahepatic CD8 T‐lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients (2004) (19)
- Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data. (2020) (19)
- Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis (2019) (19)
- Virus–drug interactions—molecular insight into immunosuppression and HCV (2012) (19)
- Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (2017) (19)
- On‐treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks (2009) (19)
- Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. (2013) (19)
- 86 SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS (2009) (19)
- Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir (2012) (19)
- Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure (2016) (19)
- Gene Expression Profiling To Predict and Assess the Consequences of Therapy-Induced Virus Eradication in Chronic Hepatitis C Virus Infection (2014) (19)
- Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. (2022) (18)
- Comprehensive analysis of long non-coding RNA-messenger RNA-microRNA co-expression network identifies cell cycle-related lncRNA in hepatocellular carcinoma (2019) (18)
- Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma. (2020) (18)
- ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. (2008) (18)
- Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian randomization study. (2017) (18)
- Is combination therapy with lamivudine and interferon-alpha superior to monotherapy with either drug? (2001) (18)
- A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96 (2017) (18)
- Tight Control of STAT5 Activity Determines Human CD34-Derived Interstitial Dendritic Cell and Langerhans Cell Development (2011) (17)
- HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection (2019) (17)
- Relationship between hepatitis B core‐related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues (2019) (17)
- Prolonged antiviral therapy for hepatitis B virus‐infected health care workers: a feasible option to prevent work restriction without jeopardizing patient safety (2007) (17)
- A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook (2022) (17)
- Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B (2019) (17)
- Changing perspectives in portal vein thrombosis. (2000) (17)
- The intrahepatic immune response during chronic hepatitis B infection can be monitored by the fine-needle aspiration biopsy technique. (2003) (16)
- Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy (2020) (16)
- Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. (2020) (16)
- Hepatitis B core‐related antigen monitoring during peginterferon alfa treatment for HBeAg‐negative chronic hepatitis B (2019) (16)
- Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV‐DNA suppression (2007) (16)
- Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). (2016) (16)
- Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients (2017) (16)
- Negative Regulation of Hepatitis C Virus Specific Immunity Is Highly Heterogeneous and Modulated by Pegylated Interferon-Alpha/Ribavirin Therapy (2012) (16)
- ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection (2015) (16)
- Challenges with stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B. (2019) (16)
- Case Report: Severe Hepatitis and Pure Red Cell Aplasia in Adult Still's Disease Good Response to Immunosuppressive Therapy (1999) (15)
- The Effect of Chronic Hepatitis B Virus Infection on BDCA3+ Dendritic Cell Frequency and Function (2016) (15)
- Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. (2019) (15)
- Ethics and hepatitis B cure research (2016) (15)
- Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection (2017) (15)
- Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps (2019) (15)
- A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results (2016) (15)
- Long‐term follow‐up of patients treated with entecavir and peginterferon add‐on therapy for HBeAg‐positive chronic hepatitis B infection: ARES long‐term follow‐up (2018) (14)
- Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon. (2007) (14)
- Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD. (2006) (14)
- Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence (2018) (14)
- Graves' hyperthyroidism in a patient with primary sclerosing cholangitis. Coincidence or combined pathogenesis? (1998) (14)
- World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. (2016) (14)
- The impact of the first, second and third waves of covid‐19 on hepatitis B and C testing in Ontario, Canada (2021) (14)
- Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis (2020) (14)
- Seizures associated with low-dose alpha-interferon. (1990) (13)
- Hepatitis C treatment and liver cancer recurrence: cause for concern? (2017) (13)
- Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication (2019) (13)
- Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. (1993) (13)
- Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study (2019) (13)
- Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial (2017) (13)
- Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study (2019) (13)
- Hepatitis C Core-Antigen Testing from Dried Blood Spots (2019) (13)
- Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B (2007) (13)
- Factors Associated With Progression and Outcomes of Early-stage Primary Biliary Cholangitis. (2020) (13)
- Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B (2019) (13)
- Liver Contrast-Enhanced Ultrasound Improves Detection of Liver Metastases in Patients with Pancreatic or Periampullary Cancer. (2015) (13)
- Analysis of the transcriptome and immune function of monocytes during IFNα-based therapy in chronic HCV revealed induction of TLR7 responsiveness. (2014) (12)
- Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon &agr;-2a: progressive decrease in hepatitis B surface antigen in responders (2012) (12)
- Idiopathic Noncirrhotic Portal Hypertension. (2019) (12)
- P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF) (2014) (12)
- 366 PREVALENCE AND SEVERITY OF KIDNEY DYSFUNCTION IN PATIENTS WITH CHRONIC HEPATITIS B IN EUROPE: DATA FROM THE EUROPEAN VIRGIL COHORT (2011) (12)
- Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss (2020) (12)
- Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies. (2007) (12)
- Interferon‐alpha therapy for chronic hepatitis B: Early response related to pre‐treatment changes in viral replication (2001) (12)
- Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. (2019) (12)
- Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive study (2020) (12)
- O3 ADDING PEGINTERFERON TO ENTECAVIR INCREASES RESPONSE RATES IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: WEEK 96 RESULTS OF A GLOBAL MULTICENTER RANDOMISED TRIAL (ARES STUDY) (2014) (12)
- DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV or HCV, with or without HIV Co-Infection. (2020) (12)
- Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. (2021) (12)
- HLA‐C and KIR combined genotype as new response marker for HBeAg‐positive chronic hepatitis B patients treated with interferon‐based combination therapy (2016) (11)
- Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real‐World Study (2021) (11)
- Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver (2021) (11)
- Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy. (2015) (11)
- Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us? (2009) (11)
- Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. (2017) (11)
- Intrahepatic natural killer cell activation, but not function, is associated with HBsAg levels in patients with HBeAg‐negative chronic hepatitis B (2014) (11)
- Peginterferon-lambda for the treatment of COVID-19 in outpatients (2020) (10)
- P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis (2015) (10)
- The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. (2012) (10)
- [Reversibility of hepatic fibrosis]. (2014) (10)
- The response to TLR ligation of human CD16⁺CD14⁻ monocytes is weakly modulated as a consequence of persistent infection with the hepatitis C virus. (2011) (10)
- Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design (2012) (10)
- Diet-dependent acid load - the missing link between an animal protein-rich diet and non-alcoholic fatty liver disease? (2019) (10)
- Time to make the change from 'primary biliary cirrhosis' to 'primary biliary cholangitis'. (2015) (10)
- Genetic polymorphisms in innate immunity receptors do not predict the risk of bacterial and fungal infections and acute rejection after liver transplantation (2013) (10)
- Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues (2013) (10)
- Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment (2021) (10)
- GS12 - A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Positive Chronic Hbv: Week 48 Efficacy and Safety Results (2016) (10)
- Experimental Hbsag/Anti-Hbs Complex Assay for Prediction of Hbeag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon and Adefovir (2014) (10)
- 15 BASELINE HBsAg LEVEL PREDICT HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS (2009) (10)
- Role of Autophagy in Chronic Liver Inflammation and Fibrosis. (2019) (9)
- Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion (2019) (9)
- 8 EARLY PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE PATIENTS: THE ROLE OF ON-TREATMENT HBSAG AND HBV DNA LEVELS (2010) (9)
- ENTECAVIR AND TENOFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B : RESCUE THERAPY IN PATIENTS WITH ADVANCED FIBROSIS AND MULTIPLE PREVIOUS TREATMENT FAILURES. RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (9)
- [Management and treatment of pregnant women with hepatitis B]. (2009) (9)
- Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes. (2019) (9)
- Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients (2020) (9)
- Flares during long‐term entecavir therapy in chronic hepatitis B (2016) (9)
- Endogenous IFNλ in viral hepatitis patients. (2014) (9)
- Psychiatric Side Effects and Fluctuations in Serotonergic Parameters in the Treatment of Chronic Hepatitis C Infection (2012) (9)
- How to achieve immune control in chronic hepatitis B? (2014) (9)
- Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time (2020) (9)
- 71 POLYMORPHISMS AT RS12979860 AND RS12980275 NEAR PREDICT SEROLOGICAL RESPONSE TO (PEG-)INTERFERON IN HBEAG-POSITIVE CHRONIC HEPATITIS B (2011) (9)
- Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use. (2013) (8)
- Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use (2018) (8)
- 737 POLYMORPHISMS NEAR THE IL28B GENE ARE NOT ASSOCIATED WITH RESPONSE TO PEGINTERFERON IN HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS (2013) (8)
- In vivo immunization following virus suppression: a novel approach for inducing immune control in chronic hepatitis B * (2003) (8)
- Relapse after treatment with peginterferon α-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B (2007) (8)
- Early changes of the portal tract on microcomputed tomography images in a newly‐developed rat model for Budd–Chiari syndrome (2008) (8)
- Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase (2020) (8)
- Ultra long-term follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B virus infection. (2020) (8)
- Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial. (1993) (8)
- NK cells in self‐limited HCV infection exhibit a more extensively differentiated, but not memory‐like, repertoire (2017) (8)
- EASL clinical practice guidelines on the management of chronic hepatitis B: The need for liver biopsy (2009) (7)
- Role of anticoagulant therapy in liver disease (2013) (7)
- Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. (2022) (7)
- Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype (2013) (7)
- Coarse vs. fine needle aspiration biopsy. (2004) (7)
- Quantitative measurement of HBeAg in chronic hepatitis B: A comparison between a radioimmunoassay a fluorescence ELISA and a chemiluminescence ELISA (1995) (7)
- Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B. (2021) (7)
- Liver safety assessment in clinical trials of new agents for chronic hepatitis B (2019) (7)
- Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients. (2013) (7)
- Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients. (2013) (7)
- Comments on the EASL practice guidelines for the management of chronic hepatitis B: controversies in interferon-based therapy. (2009) (7)
- Survival and prognostic indicators in HBsAg-positive liver cirrhosis (1991) (7)
- In vivo immunization in combination with peg‐interferon for chronic hepatitis B virus infection (2007) (7)
- Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort (2021) (6)
- The Inflammatory Cytokine Profile Associated with Liver Damage is Broader and Stronger in Chronic Hepatitis B Patients Compared to Acute Hepatitis B Patients. (2021) (6)
- PREDICTION OF RESPONSE TO PEGINTERFERON-ALFA IN HBEAG POSITIVE CHRONIC HEPATITIS B: A MODEL BASED ON 721 PATIENTS (2008) (6)
- Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada. (2019) (6)
- BDCA3 expression is associated with high IFN‐λ production by CD34+‐derived dendritic cells generated in the presence of GM‐CSF, IL‐4, and/or TGF‐β (2015) (6)
- Liver failure after delivery (2005) (6)
- PI 3 K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function Running title : PI 3 K-PKB promotes pDC development and function (2012) (6)
- Fibrinogen γ’ and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis (2013) (6)
- Low incidence of retinopathy during peginterferon alpha-2b and lamivudine therapy for chronic hepatitis B. (2006) (6)
- Risk of infections during interferon‐based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (2015) (6)
- Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes (2020) (6)
- Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study (2020) (6)
- [Non-cirrhotic portal hypertension: rare cause of upper gastrointestinal bleeding]. (2010) (6)
- P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC) (2015) (6)
- Patient Knowledge, Beliefs and Barriers to Hepatitis B Care: Results of a Multicenter, Multiethnic Patient Survey (2020) (6)
- Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues (2016) (6)
- Sustained virological response to treatment in patients with chronic hepatitis C--reply. (2013) (6)
- The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued. (2011) (5)
- Evaluation of IL-28B Polymorphisms and Serum IP-10 in Hepatitis C Infected Chimpanzees (2012) (5)
- Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data (2019) (5)
- Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion (2019) (5)
- Behavioral Patterns of Total Serum Bilirubin Prior to Major Clinical Endpoints in 3529 Patients with Primary Biliary Cholangitis (2016) (5)
- Bilirubin is predictive of transplant-free survival even within the normal range in primary biliary cholangitis patients (2017) (5)
- HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients (2018) (5)
- P510 GASTROINTESTINAL ISCHEMIA IN PATIENTS WITH ACUTE AND CHRONIC PORTAL VEIN THROMBOSIS (2014) (5)
- Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV (2021) (5)
- O115 PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE (2014) (5)
- Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B (2021) (5)
- The Budd-Chiari syndrome. (2004) (5)
- Safety and Antiviral Activity of JTK-652: A Novel HCV Infection Inhibitor (2010) (5)
- Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study (2022) (5)
- IFN-α Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T cell Proliferation. (2020) (5)
- Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients. (2022) (5)
- Incidence and prediction of HBsAg seroclearance in a prospective multi‐ethnic HBeAg‐negative chronic hepatitis B cohort (2021) (5)
- Type I and III interferons enhance IL-10 receptor expression on human monocytes and macrophages , resulting in IL-10-mediated suppression of TLR-induced IL-12 p 70 production (2012) (5)
- P677 HEPATIC STEATOSIS DOES NOT PREDICT REGRESSION OF LIVER CIRRHOSIS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2014) (4)
- 932 FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER FIBROSIS (2012) (4)
- 544 A EUROPEAN FIELD STUDY OF THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AS MONOTHERAPY IN PATIENTS WITH PRIOR FAILURE TO OTHER NUCLEOSIDE/NUCLEOTIDE ANALOGUES (2012) (4)
- Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells (2023) (4)
- Controversy on the role of FoxP3⁺ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. (2014) (4)
- What is on the horizon for treatment of chronic hepatitis C? (2008) (4)
- Hepatitis B Core-Related Antigen Levels Predict Pegylated Interferon-α Therapy Response in HBeAg-Positive Chronic Hepatitis B (2020) (4)
- 446 Viral dynamics during PEG-interferon alone and in combination with lamivudine (2004) (4)
- Gradual increase in platelets following sustained virological response among patients with HCV-induced advanced hepatic fibrosis (2013) (4)
- Immunomodulation and RNA interference alter hepatitis B virus–specific CD8 T‐cell recognition of infected HepG2‐NTCP (2021) (4)
- Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B (2019) (4)
- Similar Frequencies, Phenotype and Activation Status of Intrahepatic NK Cells in Chronic HBV Patients after Long-Term Treatment with Tenofovir Disoproxil Fumarate (TDF) (2016) (4)
- Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study (2020) (4)
- P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study (2015) (4)
- Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements (2018) (4)
- Reducing Read Time of Point of Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. (2020) (4)
- Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study (2016) (4)
- O132 EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDY (2014) (4)
- A randomized controlled trial of US vs US + biomarkers for the diagnosis of hepatocellular carcinoma: an interim report (2017) (4)
- Kinetic Analyses of Antiviral Suppression by NS5A Inhibitors Reveal Early and Potent Inhibition of Viral Assembly and Release of Infectious Virus The rs2294918 K434E PNPLA3 Polymorphism is associated with Nonalcoholic Fatty Liver and Steatohepatitis (2013) (4)
- Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-Exposure Prophylaxis. (2021) (4)
- HBV DNA suppression in HBeAg‐positive chronic hepatitis B patients treated with peginterferon or placebo (2011) (4)
- Pseudo-Budd-Chiari Syndrome: decompensated alcoholic liver disease mimicking hepatic venous outflow obstruction. (2002) (4)
- Effects of on‐treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection (2021) (3)
- INSULIN RESISTANCE, SERUM ADIPOKINES AND THE RISK OF FIBROSIS PROGRESSION IN PATIENTS TRANSPLANTED FOR HEPATITIS C: A PROSPECTIVE COHORT STUDY: 184 (2008) (3)
- Eltrombopag for thrombocytopenic patients with chronic HCV infection. (2014) (3)
- The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time (2017) (3)
- Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis (2022) (3)
- Real-World Medical Costs of Antiviral Therapy Among Patients With Chronic Hcv Infection and Advanced Hepatic Fibrosis. (2015) (3)
- Sustained Virological Response Improves Overall Survival in Chronic Hepatitis C Patients with Advanced Fibrosis (2011) (3)
- Continuous Interferon-α2B Infusion in Combination with Ribavirin for Chronic Hepatitis C in Treatment-Experienced Patients (2012) (3)
- [Chronic hepatitis-b-virus infections: new options for antiviral therapy]. (1999) (3)
- Animal protein is the most important macronutrient associated with non-alcoholic fatty liver disease in overweight participants: The Rotterdam Study (2017) (3)
- Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. (2017) (3)
- Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials (2021) (3)
- Acute hepatitis C infection: an indication for alfa interferon therapy? (2000) (3)
- 203 Combined cytolytic and noncytolytic intrahepatic CD8 T-lymphocyte reactivity is important for response to antiviral therapy in chronic hepatitis B patients (2003) (3)
- OC-030 Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study (2014) (3)
- Real‐world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (3)
- Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study (2021) (3)
- 753 BASELINE HBsAg PREDICTS HBsAg LOSS AFTER 2 YEARS OF TREATMENT-FREE FOLLOW-UP IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON alfa-2a AND ADEFOVIR (2013) (3)
- 1050 EXCLUSION OF THE PERCUTANEOUS LIVER BIOPSY FROM THE MANAGEMENT OF CHRONIC HEPATITIS B AND C PATIENTS: ARE ESSENTIAL SECONDARY DIAGNOSES BEING MISSED? (2012) (3)
- GI ischemia in patients with portal vein thrombosis: a prospective cohort study. (2016) (3)
- Durability of hbeag seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy (2001) (3)
- Pegylated interferon-alpha2b and lamivudine in hepatitis B e antigen-positive chronic hepatitis B. (2005) (3)
- The GLOBE score identifies PBC patients at increased risk of liver transplantation or death during follow-up (2016) (3)
- [83] TREATMENT OF BUDD CHIARI SYNDROME WITH TIPS. LONG-TERM RESULTS IN 124 PATIENTS AND EVALUATION OF PROGNOSTIC FACTORS (2007) (3)
- IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) (2020) (3)
- Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study (2017) (3)
- HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B (2018) (3)
- 504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS (2013) (3)
- Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression. (2014) (3)
- 941 JTK-652 IS A NOVEL HCV ENTRY INHIBITOR: RESULTS OF A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY IN CHRONIC HEPATITIS C PATIENTS (2009) (3)
- Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes (2018) (2)
- Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study (2020) (2)
- Characteristics of older patients with immunotolerant chronic hepatitis B virus infection. (2022) (2)
- World gastroenterology organisation practice guideline - hepatitis B September 2008 (2009) (2)
- Evidence for an Enhanced Fibrinolytic Capacity in Liver Cirrhosis Measured with a New Global Fibrinolysis Test in Whole Blood. (2006) (2)
- Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study (2017) (2)
- Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid (2022) (2)
- A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NAÏVE PATIENTS (2018) (2)
- RISK SCORE FOR HEPATOCELLULAR CARCINOMA IN CAUCASIANS WITH CHRONIC HEPATITIS B UNDER 5-YEAR ENTECAVIR OR TENOFOVIR THERAPY (2015) (2)
- NUCLEIC ACID POLYMER THERAPY FOR HBV - STRONG HBSAG DECLINE BUT MANY UNANSWERED QUESTIONS. (2020) (2)
- Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection (2020) (2)
- [Alpha-interferon antiviral treatment in 100 patients with chronic hepatitis B]. (1992) (2)
- Pathogenic CD8 T cells defined by longitudinal liver sampling in chronic hepatitis B patients starting antiviral therapy (2021) (2)
- Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B (2021) (2)
- Levels of Alkaline Phosphatase and Bilirubin are Surrogate Endpoints of Outcomes of Patients with Primary Biliary Cirrhosis – an International Follow-up Study Short title : Alkaline phosphatase and bilirubin as surrogate endpoints in PBC (2014) (2)
- 739 ALT FLARES DURING TREATMENT WITH PEGINTERFERON LAMBDA OR PEGINTERFERON alfa IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B INFECTION (CHB) (2013) (2)
- Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool (2020) (2)
- Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions? (2017) (2)
- Switching lamivudine resistant chronic Hepatitis B patients from tenofovir to adefovir results in less potent HBV DNA suppression (2006) (2)
- Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America (2020) (2)
- Alpha-interferon for chronic hepatitis B infection: increased efficacy of prolonged treatment (1998) (2)
- LBP-02-Association between HBsAg loss and long-term clinical outcome in chronic hepatitis B: a systematic review and meta-analysis analysis (2019) (2)
- Hepatitis B virus genotypes and response to interferon alpha treatment in chronic hepatitis B. (2001) (2)
- CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus (2010) (2)
- 750 A COMPARISON OF TWO ASSAYS FOR QUANTIFICATION OF HEPATITIS B SURFACE ANTIGEN IN SERUM OF PATIENTS WITH CHRONIC HEPATITIS B (2011) (2)
- Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment (2017) (2)
- 746 NARLAPREVIR AND PEGINTERFERON ALFA-2B FOR 2 WEEKS IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS, FOLLOWED BY PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR 24/48 WEEKS: FINAL RESULTS (2010) (2)
- Chronic HBV treatment with one year of pegylatyed-interferon alpha-2b (PEG-IFN) has a comparable safety profile to short term conventional interferon alpha-2b (2003) (2)
- Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study (2014) (2)
- Averting hepatocellular carcinoma in chronic hepatitis B with antiviral therapy: tipping the balance or not yet? (2014) (2)
- Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials (2020) (2)
- 1050 HUMAN LIVER CARCINOMAS RECRUIT MESENCHYMAL STEM/STROMAL CELLS THAT CAN PROMOTE TUMOR GROWTH VIA PARACRINE SIGNALING (2013) (2)
- Future Therapy for HBV: Role of Cell Cycle Inhibitors (2016) (2)
- P1045 ESTIMATING THE PROBABILITY OF RESPONSE TO PEG-INTERFERON THERAPY IN HBeAg-POSITIVE CHRONIC HEPATITIS B: THE EPIC-B STUDY (2014) (2)
- 447 Liver histology in chronic hepatitis B patients after 1 year of treatment with pegylated interferon alpha-2B in combination with lamivudine or placebo (2004) (2)
- PS-056-Higher relapse and retreatment rates in patients who started as HBeAg positive than negative after stopping long-term nucleos (t) ide analogue therapy: results from the randomized controlled STOP study (2019) (2)
- 426 Paired measurements of quantitative hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients (2004) (2)
- Alkaline phosphatase normalization is associated with a decreased risk for liver transplantation and death in patients with primary biliary cholangitis (2018) (2)
- Tumor Necrosis Factor Alpha Inhibits the Suppressive Effect of Regulatory T Cells on the Hepatitis B Virus– Specific Immune Response (2007) (2)
- 19 ANTIVIRAL EFFECT OF ENTECAVIR: RESULTS FROM 160 CHRONIC HEPATITIS B PATIENTS IN AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (2)
- Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease (2012) (1)
- Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment (2010) (1)
- [Fatal fibrosing cholestatic hepatitis following renal transplantation]. (2002) (1)
- [Portal vein thrombosis: causes and treatment]. (1999) (1)
- [488] WITHDRAWAL FLARES AFTER TREATMENT WITH PEGINTERFERON ALPHA-2b ALONE OR IN COMBINATION WITH LAMIVUDINE IN HBeAg-POSITIVE CHRONIC HEPATITIS B (2007) (1)
- Incidence and Impact of Decompensating Events in Primary Biliary Cirrhosis : Results of an International Follow Up Study of 3030 Patients (2015) (1)
- Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus‐infected patients with low ALT levels in the absence of significant fibrosis—authors' reply (2021) (1)
- Preface. Hepatitis C infection. (2012) (1)
- HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. (2019) (1)
- Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study (2022) (1)
- O232: Entecavir vs the Tenofovirs (TDF and TAF) (2014) (1)
- Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B (2022) (1)
- Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening (2022) (1)
- LO44: Birth cohort hepatitis C screening in an academic emergency department in Canada: preliminary results (2020) (1)
- Role of multiple regulatory T cell populations in controlling peripheral blood and liver immunity to human hepatitis C virus infections (2009) (1)
- [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma]. (2002) (1)
- Adefovir serum levels do not differ between responders and nonresponders (2011) (1)
- Interferon-alpha therapy in chronic hepatitis B: early monitoring of HBeAg may help to decide whether to stop or to prolong therapy (1999) (1)
- 1145 Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection (2003) (1)
- How effective is adefovir dipivoxil plus lamivudine for the treatment of lamivudine-resistant chronic hepatitis B? (2008) (1)
- THU-389-Assessment of hepatitis C screening strategies in different community settings in a Canadian metropolitan area (2019) (1)
- 543 PREDICTION OF RESPONSE TO PEGINTERFERON FOR HBEAG-POSITIVE CHRONIC HEPATITIS B USING QUANTITATIVE SEROLOGY: HBEAG VERSUS HBSAG (2012) (1)
- 931 PREDICTION OF LONG-TERM SURVIVAL IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS USING STANDARD LABORATORY TESTS (2012) (1)
- 1102 THE POTENT BILE ACID SEQUESTRANT COLESEVELAM (CHOLESTAGEL®) IS NOT EFFECTIVE IN CHOLESTATIC PRURITUS. RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED TRIAL (2010) (1)
- Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario. (2022) (1)
- Hepatitis C virus‐specific immune responses following direct‐acting antivirals administered during recent hepatitis C virus infection (2022) (1)
- Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients (2020) (1)
- Elevated serum levels of soluble CD14 in HBeAg‐positive chronic HBV patients upon Peginterferon treatment are associated with treatment response (2019) (1)
- Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B. (2022) (1)
- FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test (2019) (1)
- ID: 256 Evidence for an enhanced fibrinolytic capacity in cirrhosis measured with a new global fibrinolysis test in whole blood. (2006) (1)
- Alpha‐interferon for chronic hepatitis B infection: increased efficacy of prolonged treatment (1998) (1)
- Presence of Anti-Interferon Antibodies is Not Associated with Non-Response to Pegylated Interferon Treatment in Chronic Hepatitis B (2014) (1)
- Outcome of western patients with idiopathic non-cirrhotic portal hypertension (INCPH) is not determined by complications of portal hypertension: results of a large observational study (2010) (1)
- DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment (2018) (1)
- Dynamic Characterization of Human Livers during ex vivo Machine Perfusion (2014) (1)
- Younger age and language barriers are associated with nonadherence to clinical follow‐up in hepatitis B treatment (2018) (1)
- Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection. (2020) (1)
- P1180 : Identification of pbc patients in need of additional therapy during the course of UDCA treatment -an international multicenter study (2015) (1)
- A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results (2017) (1)
- High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. (2015) (1)
- FRI-056-Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of early real-world experience (2019) (1)
- Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (2017) (1)
- Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis (2017) (1)
- The antiviral effect of repeated courses of alpha interferon treatment in chronic hepatitis B (1991) (1)
- Sustained virological suppression and improved renal function with reduced dose tenofovir disoproxil fumarate in renally compromised patients with chronic hepatitis B (2018) (1)
- Prediction of response to peginterferon for HBeAg-positive chronic hepatitis B using quantitative serology: HBeAg versus HBsAg (2012) (1)
- O116 HEPATITIS B SURFACE ANTIGEN (HBsAg) LEVELS DIFFER ACROSS HBV GENOTYPE AND PHENOTYPE: RESULTS FROM THE ADULT COHORT STUDY OF THE NIDDK-SPONSORED HEPATITIS B RESEARCH NETWORK (2014) (1)
- Improved Platelet Count and Smaller Spleen Size Long After Sustained Virological Response in Chronic Hepatitis C Patients With Advance Fibrosis (2011) (1)
- Early PEG-interferon-related ALT flares of high magnitude lead to HBsAg decline and loss. A study of 639 chronic hepatitis B patients (2020) (1)
- Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor (2013) (1)
- O160 RAPAMYCIN AND EVEROLIMUS FACILITATE HEPATITIS E VIRUS REPLICATION REVEALING A HEPATOCYTE-SPECIFIC PI3K–AKT–mTOR-DEPENDENT DEFENSE MECHANISM (2014) (1)
- PS-128-Risk of gall bladder cancer in patients with primary sclerosing cholangitis and gall bladder polyps: an opportunity to revisit the guidelines (2019) (1)
- 1235 HIGH PRE-TRANSPLANT HEV SEROPREVALENCE IN HCV INFECTED LIVER TRANSPLANT RECIPIENTS; EVIDENCE FOR HCV TREATMENT PROTECTION AGAINST DEVELOPMENT OF CHRONIC HEV INFECTION (2013) (1)
- P1077 HIGH VIROLOGICAL RELAPSE RATE AFTER NUCLEOS(T)IDE ANALOGUE DISCONTINUATION IN CHRONIC HEPATITIS B (2014) (1)
- Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals? (2017) (1)
- FRI-190-Incidence and predictors of flares after discontinuing nucleos (t) ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP study (2019) (1)
- 936 Distinct intrahepatic immunological environment in chronic viral hepatitis analysed by flow cytometry of fine-needle-aspiration-biopsies (2003) (1)
- Cost-effectiveness analysis of hepatocellular carcinoma screening in hepatitis C cirrhosis after sustained viral response (2018) (1)
- 383 HEPATITIS B AWARENESS AND SCREENING PROGRAMMES FOR CHINESE COMMUNITIES IN THE NETHERLANDS: SUCCESSFUL IDENTIFICATION OF PATIENTS WITH ACTIVE LIVER DISEASE (2011) (1)
- P0669 : Consolidation therapy with entecavir can prevent post-treatment HBsAg rebound in HBeAg-positive chronic hepatitis B patients treated with peginterferon alpha (2015) (1)
- 107 INSULIN RESISTANCE, SERUM ADIPOKINES AND THE RISK OF FIBROSIS PROGRESSION IN PATIENTS TRANSPLANTED FOR HEPATITIS C: A PROSPECTIVE COHORT STUDY (2008) (0)
- Characterisation of baseline complement values in patients with chronic hepatitis B virus infection in the phase IIb B-clear study (2022) (0)
- Sa1496 - 1 Year Safety and Efficacy Data in Chronic Hbv Patients with Risk Factors for Tenofovir Disoproxil Fumarate (TDF) after Switching from TDF to Tenofovir Alafenamide (TAF) (2018) (0)
- Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B (2017) (0)
- Iconographies supplémentaires de l'article : GI ischemia in patients with portal vein thrombosis: a prospective cohort study (2016) (0)
- Cost-Effectiveness Analysis of Annual Versus Biannual Ultrasound Surveillance for Hepatocellular Carcinoma in Patients with Hepatitis C Related Cirrhosis after Sustained Viral Response (2017) (0)
- Time trends in major hepatic complications in primary biliary cholangitis : incidence and transplant-free survival (2017) (0)
- 308 TUMOR-INFILTRATING REGULATORY T CELLS FAVOR TUMOR DEVELOPMENT BY SUPPRESSING LOCAL TUMOR-SPECIFIC T CELL RESPONSES IN PRIMARY AND METASTATIC LIVER CANCER (2012) (0)
- Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis. (2023) (0)
- Erratum: Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis (2009) (0)
- Response Guided Treatment for Peginterferon in Chronic Hepatitis B (2013) (0)
- 9 Virale hepatitis (2009) (0)
- The inhibition by regulatory T cells of the immune response against HBV is partially HBV-specific but not mediated through IL10 and TGF-?? (2006) (0)
- 33 – Treatment of Hepatitis B (2018) (0)
- Efficacy of interferon-alpha for the treatment of lamivudine resistant chronic HBeAg-positive Hepatitis B virus infection. (2006) (0)
- [504] SWITCHING LAMIVUDINE RESISTANT CHRONIC HEPATITIS B PATIENTS FROM TENOFOVIR TO ADEFOVIR RESULTS IN HBVDNA RELAPSE WITHOUT EVIDENCE OF GENOTYPIC RESISTANCE (2007) (0)
- 411 A NEW HBsAg/ANTI-HBs IMMUNE COMPLEX ASSAY PREDICTS HBeAG LOSS IN CHRONIC HEPATITIS B PATIENTS (2013) (0)
- Reply (2020) (0)
- Serum hepatitis B virus RNA level is associated with hepatitis B virus genotype and BCP mutations in untreated patients with HBeAg positive chronic hepatitis B (2017) (0)
- 552 FINITE PEGINTERFERON RESULTS IN HIGHER SEROLOGICAL, BUT NOT VIROLOGICAL, RESPONSE RATES WHEN COMPARED TO CONTINUOUS ENTECAVIR IN HBEAG-POSITIVE CHRONIC HEPATITIS B (2012) (0)
- EFFICACY AND TOLERANCE OF TENOFOVIR DISOPROXIL FUMARATE PLUS EMTRICITABINE COMBINATION IN PATIENTS WITH CHRONIC HEPATITIS B - A EUROPEAN MULTICENTER STUDY (2010) (0)
- Hepatologists have addressed these severe complications of liver diseases in many ways, but unfortunately the impact of old and modern therapies on survival once complications of liver disease are manifest, is only minor. Preface. (2008) (0)
- Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study. (2018) (0)
- Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B (2022) (0)
- Reduced expansion of HBV specific CD8+ T cells by myeloid dendritic cells isolated from chronic HBV patients (2006) (0)
- Use of HBV RNA and hepatitis B core-related antigen to predict change in serological status and disease activity in CHB. (2023) (0)
- IFN-Based Therapy and Management of Patients (2016) (0)
- P644 PREDICTION OF ALT FLARES IN THE NATURAL HISTORY OF CHRONIC HEPATITIS B INFECTION: A PROSPECTIVE COHORT STUDY FROM THE NIDDK HEPATITIS B RESEARCH NETWORK (HBRN) (2014) (0)
- P0488 : Dissecting the complexity of interferon response that cross talks with 4E-BP1 in hepatitis E virus infection (2015) (0)
- Liverspecific immunopathology; mechanism and therapeutic modulation (2008) (0)
- IL28B polymorphism and hepatitis C: a genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects? (2012) (0)
- Pharmacokinetics and antiviral activity of PHX1766, a novel hepatitis C virus protease inhibitor using an accelerated Phase 1 study design (2012) (0)
- A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis (2018) (0)
- Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. (2023) (0)
- Indicators of survival in patients with portal vein thrombosis (1999) (0)
- 760 ENTECAVIR TREATMENT IS EFFECTIVE IN PATIENTS WITH PREVIOUS ADEFOVIR TREATMENT: RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (0)
- P0662 : 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials (2015) (0)
- 415 SNP rs12356193 AND PLASMA CARNITINE LEVELS ARE ASSOCIATED WITH HBsAg LOSS AFTER COMBINATION TREATMENT WITH PEGINTERFERON AND ADEFOVIR (2013) (0)
- Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study (2018) (0)
- incidence and Impact of Decompensating Events in Primary Biliary Cirrhosis - Results of an International Follow Up Study of 3030 Patients. : 73 (2015) (0)
- Low rates of prenatal testing for hepatitis B and C infections in Ontario, Canada (2018) (0)
- ROLE OF APE/REF-1 IN HEPATOCELLULAR CARCINOMA PROGRESSION: A CANDIDATE THERAPEUTIC TARGET? (2015) (0)
- Response to Dr. Senzolo et al. (2006) (0)
- PS1-102 Both type I and III interferon potentiate IL-10 signaling, but differ in their ability to modulate IL-12 production by TLR-activated human monocytes and macrophages (2011) (0)
- Characteristics and renal function in patients with chronic hepatitis B virus infection: baseline data from the phase 2b B-Clear study (2022) (0)
- Addition of (pegylated) interferon to entecavir increases response in treatment naïve HBeAg-positive patients with chronic hepatitis B (2017) (0)
- Reply: (2008) (0)
- Association between ursodeoxycholic acid therapy and prolonged transplant-free survival among patients with primary biliary cholangitis a number needed to treat analysis (2016) (0)
- FRI-163-Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study (2019) (0)
- Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B (2022) (0)
- Aetiology, treatment and prognosis of patients with combined Budd-Chiari syndrome and portal vein thrombosis (2003) (0)
- 640 FIBROSCAN SUPERIOR TO APRI IN DETECTING SIGNIFICANT LIVER FIBROSIS IN CHRONIC HEPATITIS B AND C PATIENTS (2008) (0)
- Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk. (2021) (0)
- PEGINTERFERON THERAPY AND PREDICTS TREATMENT RESPONSE (2012) (0)
- THU-305-Comparing perceptions of illness among patients with chronic liver disease (2019) (0)
- Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial. (2023) (0)
- P0490 : NK cell dynamics in chronic hepatitis B patients are associated with HBsAg clearance after combination treatment with peginterferon ALFA-2A and adefovir (2015) (0)
- BRIEF COMMUNICATION External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study (2013) (0)
- Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot? (2023) (0)
- Mitochondrial cardiotoxicity of a prototype HCV NS3-protease inhibitor is characterized by a specific electrocardiographic signature in mice (2012) (0)
- Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection (2023) (0)
- Editorial Potency of tenofovir in chronic hepatitis B: Mono or combination therapy? q (2008) (0)
- End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients. (2022) (0)
- CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma (2019) (0)
- A212 INCIDENCE OF HEPATITIS C VIRUS INFECTIONS AMONG USERS OF HUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS (0)
- P0690 : IFN-free therapy for chronic HCV: Transcriptomics and NK cell analyses (2015) (0)
- P194 THE RISK OF HEPATITIS B-RELATED HEPATOCELLULAR CARCINOMA (HCC) IS REDUCED WITH ANTIVIRAL THERAPY: EVIDENCE FROM 3 HCC PREDICTION MODELS (2014) (0)
- Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease (2020) (0)
- Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection. (2021) (0)
- S1127 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Renal Impairment: Week 48 Results From a Phase 2 Open-Label Study (2021) (0)
- Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients (2020) (0)
- P0613 : Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection (2015) (0)
- 542 THE ENTEBE STUDY: SAFETY AND EFFICACY OF ENTECAVIR PLUS TENOFOVIR IN ADULTS WITH CHRONIC HEPATITIS B AND PREVIOUS NUCLEOS(T)IDE TREATMENT FAILURE (2012) (0)
- Biochemical patterns of alkaline phosphatase and bilirubin levels in relation to clinical outcomes in UDCA-treated PBC patients- an international study (2016) (0)
- PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy (2020) (0)
- Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. (2006) (0)
- Previous Interferon Treatment Failure is Associated with Avery Low Chance of Response to Peginterferon Retreatment in HBeAg-Positive Chronic Hepatitis B: Pooled Analysis of Two Randomized Trials (2016) (0)
- Cholestasis is not Associated with Liver Stiffness in a Population-Based Cohort (2016) (0)
- Randomisedclinicaltrial:anti-viralactivityofANA773,anoral inducerofendogenousinterferonsactingviaTLR7,inchronicHCV (2011) (0)
- Fibrinogen γ9 In the Budd-Chiari Syndrome: Results From a Multicenter Case-Control Study (2010) (0)
- 54 PRESENCE OF ONLY WILDTYPE VIRUS IS THE STRONGEST DETERMINANT OF HBVDNA UNDETECTABILITY AND HBSAG CLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON (2012) (0)
- Su1357: PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH LONG-TERM OBETICHOLIC ACID IN A TRIAL-SETTING DEMONSTRATE BETTER EVENT-FREE SURVIVAL OUTCOMES THAN EXTERNAL CONTROLS FROM THE GLOBAL PBC AND UK-PBC STUDY GROUPS (2022) (0)
- Response-guided Peginterferon Therapy for HBeAg-positive and HBeAg-negative Chronic Hepatitis B using Hepatitis B Surface Antigen Levels: A Review (2014) (0)
- 545 HEAVY ALCOHOL USE IN THE ELDERLY IS ASSOCIATED WITH HEPATIC STEATOSIS BUT ONLY RESULTS IN SIGNIFICANT FIBROSIS IN A MINORITY OF SUBJECTS (2013) (0)
- Hedgehog Pathway Targeted by Vitamin E Therapy in NASH Defining Optimal Laboratory Response Criteria in UDCA Treated Primary Biliary Cirrhosis. Results of an International Multicenter Long-term Follow-up Study (2013) (0)
- PS-189-Toronto HCC risk index and albumin predict low risk of hepatocellular carcinoma after sustained virological response in hepatitis C infection (2019) (0)
- Treatment of chronic hepatitis B: an update (2005) (0)
- JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis (2010) (0)
- Effect of antiretroviral switch from TDF to TAF on ALT, lipid profiles and renal function in HIV/HBV-coinfected individuals in a nationwide Canadian study (2022) (0)
- Toronto Hepatocellular Carcinoma Risk Index: Development of a validated clinical scoring system to predict 10-year risk of HCC in patients with cirrhosis (2015) (0)
- Delayed viral decline is associated with highest sustained response rate during PEG-interferon treatment for HBeAg-positive chronic hepatitis B (2006) (0)
- FRI-021-Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis (2019) (0)
- Determination of survival and the effect of portosystemic shunting in budd-chiari syndrome: A collaborative multicenter study (2003) (0)
- 1146 Response to alpha-interferon prolongs survival and reduces the risk of hepatocellular carcinoma in chronic hepatitis B (2003) (0)
- 774 CLOSE MONITORING OF HBsAg LEVELS HELPS CLASSIFY FLARES DURING PEGINTERFERON THERAPY AND PREDICTS TREATMENT RESPONSE (2013) (0)
- Hematologic Challenges in ICU Patients with Liver Disease and Gastrointestinal Hemorrhage (2018) (0)
- P0695 : Triple therapy for chronic HCV patients induces early activation of intrahepatic NK cells (2015) (0)
- Impact of genotype 3 on clinical outcome in patients with hepatitis C: both diabetes meliitus and liver disease progression (2017) (0)
- PS1-101 Peginterferon therapy of chronic viral hepatitis patients differentially regulates plasmacytoid dendritic cell TLR7 and TLR9 function. (2011) (0)
- Editorial: only steps away from primetime? Hepatitis B virus RNA as a routine marker to guide HBV treatment decisions—authors' reply (2021) (0)
- FRI-170-Real-world effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients in Canada (2019) (0)
- P1177 : Risk factors for hepatic decompensation in primary biliary cirrhosis - results of an international follow up study of 2326 patients (2015) (0)
- FRI-257-Making OraQuick quicker: A hepatitis C point-of-care assay reduced to five minutes for viremic individuals (2019) (0)
- P63 SMAD4-DEPENDENT REGULATION OF HEPATOCELLULAR CARCINOMA GROWTH AND PROGRESSION (2014) (0)
- Sa1522 EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY (2020) (0)
- Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase (2020) (0)
- P66 IMPDH2-TARGETED CONSTRAINT OF CELL GROWTH IN HEPATOCELLULAR CARCINOMA BY MYCOPHENOLIC ACID (2014) (0)
- PS-012-Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis (2019) (0)
- Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS) (2017) (0)
- P0983 : Association between macro-nutrient intake and presence of nonalcoholic fatty liver disease in the Rotterdam study: a population-based study (2015) (0)
- FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients (2019) (0)
- 1176 T FOLLICULAR HELPER CELLS: DO THEY PLAY A ROLE IN CHRONIC HCV? (2013) (0)
- 1021 HBSAG LEVELS DURING ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS B: PEGINTERFERON VERSUS ENTECAVIR (2010) (0)
- Polytetrafluoroethylene (ePTFE) covered and uncovered stents for TIPS in Budd???Chiari syndrome: a single center experience (2006) (0)
- Discordance between HCV RNA Assays for Week 24 HCV RNA Determination during Pegylated Interferon-α/Ribavirin Treatment for Chronic Hepatitis C (2011) (0)
- P0460 : CD3hiCD4- Vγ9/Vδ2 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B (2015) (0)
- Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum Levels of Lysyl Oxidase-Like-2 (Loxl2) (2016) (0)
- Primary Biliary Cholangitis at a Young Age : Clinical Characteristics and Prognosis (2016) (0)
- Diagnosis of acute rejection after liver transplantation by fine-needle-aspiration-biopsy (1999) (0)
- On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB (2017) (0)
- Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients (2017) (0)
- Reply to: Understanding more about hepatitis flare in chronic hepatitis B patients. (2019) (0)
- Su1473 Gastrointestinal Ischemia in Patients With Acute and Chronic Portal Vein Thrombosis: A Prospective Study (2014) (0)
- Prolonged intermittent treatment with interferon in chronic hepatitis B (1990) (0)
- Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection (2017) (0)
- 941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS – AN INTERNATIONAL, COLLABORATIVE ANALYSIS (2013) (0)
- University of Birmingham Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis (2014) (0)
- The number needed to treat to prevent one clinical event at 2 years after antiviral treatment for HCV with DAAs compared to IFN-based therapy (2018) (0)
- Cost-effectiveness modelling of birth and infant dose vaccination against hepatitis B virus in Ontario from 2020 to 2050 (2023) (0)
- HIV‐associated idiopathic non‐cirrhotic portal hypertension is an underdiagnosed disorder: results of a large cohort study (2012) (0)
- Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS) (2017) (0)
- P1147 : Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest cohorts (2015) (0)
- P5 DICHOTOMAL EFFECT OF IMMUNOSUPPRESSANTS ON HEPATITIS E VIRUS INFECTION: CALCINEURIN INHIBITORS STIMULATE BUT MYCOPHENOLIC ACID INHIBITS VIRAL REPLICATION (2014) (0)
- 551 RELATIONSHIP BETWEEN PRECORE/CORE PROMOTER MUTANTS, HBEAG LEVELS AND SEROLOGICAL RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B TREATED WITH NUCLEOS(T)IDE ANALOGUES (2012) (0)
- 735 PEGINTERFERON ADDED TO LONG-TERM NUCLEOS(T)IDE ANALOGUES ENHANCES THE DECLINE OF SERUM HBeAg AND HBsAg LEVELS IN CHRONIC HEPATITIS B (2013) (0)
- P0456 : Re-evaluation of HBV clinical phases by system biology identifies unappreciated roles for the innate immune response and B cells (2015) (0)
- P1176 INCIDENCE AND RISK FACTORS FOR INFECTIONS DURING INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED HEPATIC FIBROSIS (2014) (0)
- Session 7: Noncirrhotic Portal Hypertension (2007) (0)
- A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE (2018) (0)
- Reply (2011) (0)
- HBV Care Map for Patients Receiving Anti-CD20 Therapy (2017) (0)
- Clinical and virological studies on α-interferon treatment of chronic hepatitis type B (1993) (0)
- Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results. (2021) (0)
- Monocytes from chronic HCV patients are functionally altered with distinct regulation of the TLR4 and TLR7/8 pathways (2009) (0)
- P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
- Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: Results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study). (2023) (0)
- FRI-206-Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos (t)ide analogues (2019) (0)
- Leveraging COVID-19 vaccination to enhance hcv testing in priority populations (2021) (0)
- Reply to: "Identification of chronic hepatitis B". (2013) (0)
- Spontaneous clearance of HCV RNA after documented relapse following DAA-therapy: A case-control study (2018) (0)
- DIFFERENCES IN SELF-REPORTED QUALITY OF LIFE AMONG PATIENTS WITH AUTOIMMUNE HEPATITIS AND PRIMARY BILIARY CHOLANGITIS DURING CANADA'S STATE OF EMERGENCY RESPONSE TO COVID-19 (2020) (0)
- 1085 ABROGATION OF TUMOR-ASSOCIATED IMMUNOSUPPRESSION BY TARGETING TUMOR-INFILTRATING REGULATORY T-CELLS RESTORES IMPAIRED T CELL RESPONSES IN PATIENTS WITH LIVER CANCER (2013) (0)
- Cohesins: Novel Markers for the Efficacy of Sorafenib in Hepatocellular Carcinoma (2014) (0)
- Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis (2018) (0)
- BASIC AND TRANSLATIONAL—BILIARY Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies (2016) (0)
- Sa1525 SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY (2020) (0)
- Tu1000 Formal Hepatitis B (HBV) Education Improves Not Only Knowledge but Also Acceptance of Antiviral Therapy Among the HBV-Infected Vulnerable Patient Population (2014) (0)
- FRI-158-Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment (2019) (0)
- FRI-045-Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survival (2019) (0)
- Letter to the Editor: Entecavir Treatment Restores the Anti‐HBV Immune response? (2021) (0)
- Editorial: identifying candidates for pegylated interferon add‐on to entecavir therapy in patients with HBeAg‐positive chronic hepatitis B – authors' reply (2019) (0)
- Adefovir treatment failure is not associated with low serum drug levels (2010) (0)
- FRI-055-Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry (2019) (0)
- Liver-specific Inflammatory Signatures Predict Clinically Significant Liver Damage (2023) (0)
- P685 BASELINE LIVER BIOPSY CHARACTERISTICS ASSOCIATED WITH RESPONSE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON-ALFA AND ADEFOVIR (2014) (0)
- 1347 ASSOCIATION OF PSORIASIS WITH NONALCOHOLIC FATTY LIVER DISEASE: RESULTS FROM A POPULATION-BASED STUDY (2013) (0)
- disturbance Of The Microrna Pathway By Commonly Used Lentiviral Shrna Libraries Interferes With Screening For Novel Hepatitis C Virus Host Factors : 1045 (2010) (0)
- 957 Effect of chronic hepatitis B infection on dendritic cell (DC) function: impaired antigen presentation by myeloid DC and reduced IFN-α production by plasmacytoid DC (2003) (0)
- Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis (2018) (0)
- Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe (2022) (0)
- THU-390-Results of a birth cohort hepatitis C screening program in an academic emergency department in Canada (2019) (0)
- Antiviral combination therapy of alpha interferon and zidovudine in chronic hepatitis type b results from a randomized controlled trial (1991) (0)
- Moving from early to moderate or advanced biochemical disease stage during follow-up is associated with an increasing risk of clinical events in primary biliary cholangitis patients (2017) (0)
- Regulatory T Cells Favor Human Cancer Development by Suppressing Anti-Tumor Immunity in Primary and Metastatic Liver Malignancies: 2359 (2012) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Adefovir treatment of chronic hepatitis B patients recovers circulating numbers and function of myeloid dendritic cells (2006) (0)
- Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC) (2018) (0)
- Using Off-Treatment HBV DNA Levels to Predict Alt Relapse after Nucleos(t)ide Analogue Discontinuation: A Prospective Cohort Study (2016) (0)
- QUALITY OF LIFE AMONG PATIENTS WITH PRIMARY BILIARY CHOLANGITIS DURING CANADA'S STATE OF EMERGENCY RESPONSE TO COVID-19 (2020) (0)
- 594 VON WILLEBRAND FACTOR LEVELS AND VARIATIONS IN THE VON WILLEBRAND FACTOR GENE INDEPENDENTLY INFLUENCE LIVER STIFFNESS: THE ROTTERDAM STUDY (2013) (0)
- P0610 : Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up (2015) (0)
- 958 Hepatitis B virus genotypes in HBEAG-positive patients: geographic distribution and relation to viral replication and fibrosis (2003) (0)
- O-12 : Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients with Moderate or Severe Renal Impairment, or in End-Stage Renal Disease (ESRD) Patients on Hemodialysis (HD): Week 2 (2020) (0)
- Reply to Letter to the Editor: Stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B (GASTRO-D-19-02940). (2020) (0)
- IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2 (2021) (0)
- 505 DONOR IL28B TT-POLYMORPHISM IS ASSOCIATED WITH INCREASED INCIDENCE OF HEPATIC STEATOSIS IN LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C (2013) (0)
- A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS? (2018) (0)
- aminotransferaseB virus DNA and alanine to type of therapy and pretreatment serum antiviral therapy for chronic hepatitis B: relation Durability of HBeAg seroconversion following (2006) (0)
- Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B (2018) (0)
- and Function Human Myeloid Dendritic Cell Development B in κ A Nonredundant Role for Canonical NF (2010) (0)
- IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) (2021) (0)
- Low hepatitis B surface antigen at baseline and increased ALT levels during treatment predicts significant HBsAg decline in peginterferon alfa added to long-term nucleus(t)ice analogue. Results from two randomized controlled trials in 165 patients (2020) (0)
- S1126 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study (2020) (0)
- determinants of survival Extrahepatic portal vein thrombosis : aetiology and (2001) (0)
- Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Antigen Levels and TAFI Gene Polymorphisms in Patients with Budd-Chiari Syndrome and Portal Vein Thrombosis. (2004) (0)
- Reply to the Letter to the Editor: Is liver stiffness equal to liver fibrosis? (2016) (0)
- Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study (2017) (0)
- P1097 LONG-TERM SAFETY AND EFFICACY OF MIRAVIRSEN IN CHRONIC HEPATITIS C PATIENTS (2014) (0)
- Treatment and prognosis of Budd-Chiari syndrome combined with portal vein thrombosis. (2004) (0)
- Optimising trial design in late-stage primary biliary cholangitis : evaluating options for composite clinical endpoint studies (2019) (0)
- CHAPTER 2 MIRAVIRSEN DOSING IN CHRONIC HEPATITIS C PATIENTS RESULTS IN DECREASED MICRORNA-122 LEVEL WITHOUT AFFECTING OTHER MICRORNA ’ S IN PLASMA (2017) (0)
- ong-Term Therapy With Tenofovir Is Effective for Patients Co-Infected ith Human Immunodeficiency Virus and Hepatitis B Virus (2010) (0)
- Iconographies supplémentaires de l'article : New therapeutic agents for chronic hepatitis B (2016) (0)
- Hepatitis B virus infection. (2017) (0)
- Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database (2022) (0)
- 741 Intrahepatic NK Cell Activation is Dependent on Levels of HBsAg in Chronic HBeAg-Negative Hepatitis B (2012) (0)
- 955 The predictive value of intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients (2003) (0)
- Prediction of response based on viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B (2006) (0)
- Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy. (2023) (0)
- O79 PROTHROMBOTIC GENETIC RISK FACTORS ARE ASSOCIATED WITH LIVER STIFFNESS IN THE GENERAL POPULATION: RESULTS FROM THE ROTTERDAM STUDY (2014) (0)
- Increase in age at diagnosis of primary biliary cholangitis over the last 40 years (2017) (0)
- Serum Alanine Aminotransferase Flares In Chronic Hepatitis B: The Good and The Bad (2020) (0)
- P1211 HIGH DOSE RIBAVIRIN INFLUENCES EARLY VIRAL KINETICS AND IMPROVES SVR RATES IN CHRONIC HCV PATIENTS WHO ADHERE TO THERAPY (VIRID STUDY) (2014) (0)
- Editorial: HBV cure—the quest for biomarkers to predict off‐treatment sustained response. Authors' reply (2021) (0)
- Hepatitis B. (2018) (0)
- 498 INTRAHEPATIC HBSAG REDUCTION AFTER PEGINTERFERON TREATMENT IN HBEAG NEGATIVE AND HBEAG POSITIVE CHRONIC HEPATITIS B IS ASSOCIATED WITH SERUM HBSAG DECLINE (2012) (0)
- Pretreatment intrahepatic CD8+ cell number correlates with virological response to antiviral therapy in chronic hepatitis C (2003) (0)
- Comparison of event-free survival between DAA and IFN-based antiviral therapy for HCV, adjusted for disease severity (2018) (0)
- High dietary acid load is associated with nonalcoholic fatty liver disease (NAFLD) in a large population-based study : The Rotterdam Study (2017) (0)
- Reply (2017) (0)
- Polymorphisms of HLA-DPB1 are Associated with Long-Term Clinical Outcome in a Diverse Cohort of Chronic Hepatitis B Patients (2016) (0)
- Letter to the Editor: Reply (HEP-19-1537 and 19-1551). (2019) (0)
- THU-154-Low rate of hepatitis B reactivation among patients with chronic hepatitis C during direct acting antiviral therapy (2019) (0)
- 1086 TUMOR-INFILTRATING IL-10 PRODUCING CELLS ARE POTENT SUPPRESSORS OF THE LOCAL ANTI-TUMOR IMMUNITY IN PATIENTS WITH LIVER CANCER (2013) (0)
- Reduced Risk of Chronic Hepatitis E Infection Post Liver Transplantation in HCV Infected Patients. Evidence for HCV Treatment Protection Against Development of Chronic HEV Infection. (2013) (0)
- Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis– the Global PBC Study Group (2018) (0)
- 1049 COMPLICATION AND HOSPITALISATION PROPORTIONS AFTER PERCUTANEOUS LIVER BIOPSY: A RETROSPECTIVE COHORT STUDY ON THE EFFECT OF THE NUMBER OF PASSES (2012) (0)
- 406 – Chronic Hbv Patients Who Switched to Tenofovir Alafenamide (TAF) After Either 2 Or 3 Years of Prior Tenofovir Disoproxil Fumarate (TDF) Treatment Demonstrated Improvement in Bone and Renal Safety (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Harry L. A. Janssen?
Harry L. A. Janssen is affiliated with the following schools:
